Vivos Announces New Clinical Advisory Board and Changes to Board of Directors

Dr. Michael Bennett to Chair New Clinical Advisory Board


DENVER (February 14, 2018) – Vivos Therapeutics, a world leader in treatment for obstructive sleep apnea (OSA),  announced today that its newly formed clinical advisory board will be chaired by Dr. Michael Bennett, DDS and diplomate of both the American Board of Craniofacial Pain and the American Board of Craniofacial Dental Sleep Medicine. Dr. Bennett is also the lead practitioner at the Vivos Breathing Wellness Center in Orem, Utah.

“Mike Bennett is uniquely qualified and experienced to chair this impressive team of clinicians and professionals,” said Dr. Dave Singh, president of Vivos Therapeutics.

“Given his years of practice focused on craniofacial pain and sleep breathing disorders such as obstructive sleep apnea, we’re very pleased to have Dr. Bennett heading up our clinical advisory board,” said Kirk Huntsman, chief executive officer of Vivos. “His passion for clinical excellence in the treatment of this condition make him the perfect leader for this new team.”

Other members of the initial clinical advisory board include Dr. Dave Singh, an expert in craniofacial epigenetics who will be the keynote speaker at five major medical and dental conferences in 2018; Dr. Martha Cortes, DDS; Dr. Felix Liao; Dr. Chris Chapman, DC; Dr. Tammarie Heit, DDS; and Dr. Tara M. Griffin, DMD. All of the clinical advisory board members have many years of extensive clinical experience in treating obstructive sleep apnea.

“Our clinical advisory board will be an integral part of the success in delivering on the Vivos mission to provide powerful and innovative therapies that restore normal breathing during sleep, with the objective of bringing people back to a life full of vitality and happiness,” said Dr. Bennett.

Dr. Bennett’s appointment to the chairman role for the clinical advisory board also means that he has stepped down from his role as a member of the company’s board of directors.

For more information about Vivos, please click here.


Media Contact: Shannon Michael, SnappConner PR,


About Vivos

Founded in 2016, Vivos Therapeutics combines breakthrough technology for specially designed oral appliances with proprietary clinical protocols for obstructive sleep apnea (OSA) treatment that can restore and enhance the human airway. Because its patented FDA Class I and II medical devices are thought to be the first treatment that addresses the root causes of OSA, Vivos can improve the airway so that further clinical intervention may no longer be required in some cases. Other treatments for this insidious and dangerous condition require lifetime treatment, which has a significant impact on U.S. healthcare costs. Because the Vivos System is all-natural, non-invasive and non-pharmaceutical, many more patients will be able to receive treatment from the 750+ (and growing) independent providers who have been trained and certified in the Vivos methodology and who have already treated more than 8,000 patients. The company also is creating Vivos Breathing Wellness Centers in major metro areas, working with licensed and trained local medical and dental professionals. For more information, visit